Close
Achema middle east
swop processing & packaging

Natco Pharma wins license to manufacture, sell Nexavar in India

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

The Indian patents office has awarded a license to Natco Pharma to manufacture and sell a generic version of Bayer’s cancer treatment drug Nexavar.

As per the Indian Patents Act, Natco Pharma will be able to make and sell low-cost drug in the country, through a pact with the patent holder, at a price fixed by the Controller General of Patents, Designs and Trademarks. Natco Pharma chief financial officer Baskara Narayana told The Economic Times that sales of the generic version of Nexavar are estimated to be about INR250m ($5m) to INR300m ($6m) every year once it is launched.

Narayana also told NDTV Profit that sale of the drug would earn Natco Pharma 5-10% margins. Under the license, Natco must pay 6% in royalties to Bayer from the sale of the drug, which is needed by about 8,800 cancer patients in India today.

Natco said its version of generic Nexavar would cost Indian patients $175 a month, instead of about $5,600 which Bayer markets sorefinib as Nexavar under a 2008-2020 patent.

Latest stories

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »